Amorfix Life Sciences Inc. granted global rights for Biogen Idec Inc to market monoclonal antibodies to treat patients suffering from amyotrophic lateral sclerosis (ALS).

Pharming Group NV signed with Sanofi-Aventis SA and agreement to increase production capacity of its drug Ruconest (Recombinant Human C1 Esterase Inhibitor).
indicated to treat acute hereditary angioedema and reduce costs ahead of an expected European launch.

Eli Lilly & Co. acquired privately held Alnara Pharmaceuticals Inc. specialist in enzyme replacement therapy. Terms of the deal were not disclosed.

Eisai Co.and Arena Pharmaceuticals Inc. closed a deal to sell experimental drug Lorcaserin, indicated to treat obesity. The deal was closed for $140 million. The drug will be reviewed by an advisory panel on September and will make a decision whether or not to approve it on October.

Sanofi-Aventis announced agreement with California-based Metabolex Inc. for diabetes type 2 drug rights, currently in phase II, known as MBX 2982.

Bristol-Myers Squibb Co. decided to conclude development of experimental cancer drug, XL 184, indicated to treat thyroid cancer, glioblastoma and other solid tumors. The original deal with Exelixis Inc. was signed in 2008.

Takeda Pharmaceuticals Co. announced a new deal to manufacture influenza vaccines using Baxter International Inc. technology, the distribution will start on 2014.

Boehringer Ingelheim GmbH closed a deal with Neurocrine Biotechnology to develop Diabetes Type 2 drugs and other conditions.

Abbott Laboratories Inc. announced agreement with Neurocrine Biosciences Inc. to develop an endometriosis drug, a gynecological medical condition that has no cure and can cause infertility .

Forest Laboratories Inc. agreed with TrasTech Pharma Inc. an almost global license for experimental diabetes drug TTP 339 (with the exception of the Middle East and some regions of Africa) together with a series of small molecule compounds in initial phases for more than $1 billion.

Astellas Pharma Inc. announced that 87 percent of OSI Pharmaceuticals Inc. investors, accepted the $57.5 per share offer made last May 17th.

Biotechnology AMAG Pharmaceuticals Inc. and Japanese Takeda Pharmaceutical Co., announced a jointly agreement to market iron deficiency anemia drug Feraheme (Ferumoxytol) in adult patients with chronic kidney disease. The drug was approved back in June 2009.

U.S. Allergan Inc. licensed to U.S. private company Serenity Pharmaceuticals LLC, experimental drug in late-stage phase, Ser 120, to treat night-time urination.

French Sanofi-Aventis SA, agreed with US Biotechnology Exelixis Inc. exclusive license for two experimental drugs currently in initial phase, and development of several cancer drugs. The deal could pay more than one billion dollars

U.S. drugmaker Pfizer has agreed to pay up to $140 million dollars for Cytos Biotechnology Ltd. world-wide exclusive rights to market vaccines, based on Cytos biotech Immunodrug Technology.

Eli Lilly signed a licensing agreement with Canadian biotech BioMS, to develop an market the experimental drug Dirucotide, to treat advanced forms of multiple sclerosis. The deal was closed for $497 million dollars.

GlaxoSmithkline Plc secured a multimillion dollar deal with Archemix to develop and market aptamer therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

GlaxoSmithKline Plc and Dynavax Technologies Corp. signed a deal to develop first-in-class endosomal TLR inhibitors for autoimmune and inflammatory diseases.

According to Reuters, MediGene received offers from Pfizer and Eli Lilly & Co. for marketing rights to EndoTAG, a treatment for pancreatic cancer. Roche Holding AG and Amgen are reportedly expected to bid before the year ends.

Anglo-Swedish drugmaker Astra Zeneca Plc said it was ready to end a two year deal with U.S.based Abraxis BioScience Inc. for the co-promotion of breast cancer drug Abraxane.